RU2020122037A -
Method for the treatment of acute respiratory viral infection
- Google Patents
Method for the treatment of acute respiratory viral infection
Download PDF
Info
Publication number
RU2020122037A
RU2020122037ARU2020122037ARU2020122037ARU2020122037ARU 2020122037 ARU2020122037 ARU 2020122037ARU 2020122037 ARU2020122037 ARU 2020122037ARU 2020122037 ARU2020122037 ARU 2020122037ARU 2020122037 ARU2020122037 ARU 2020122037A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Александр Ильич АнтоновfiledCriticalАлександр Ильич Антонов
Priority to RU2020122037ApriorityCriticalpatent/RU2020122037A/en
Publication of RU2020122037A3publicationCriticalpatent/RU2020122037A3/ru
Publication of RU2020122037ApublicationCriticalpatent/RU2020122037A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Claims (1)
Способ лечения острой респираторной вирусной инфекции, с использованием противопротозойного препарата, отличающийся тем, что, с целью повышения эффективности лечения и уменьшения токсичности процесса лечения, выбирают жидкую форму препарата, вводят его через носовую полость в дыхательные пути пациента в виде аэрозоля, который затем с помощью дыхательных движений распределяют по всей дыхательной системе.A method for the treatment of an acute respiratory viral infection using an antiprotozoal drug, characterized in that, in order to increase the effectiveness of treatment and reduce the toxicity of the treatment process, a liquid form of the drug is selected, it is injected through the nasal cavity into the respiratory tract of the patient in the form of an aerosol, which is then used respiratory movements are distributed throughout the respiratory system.
RU2020122037A2020-06-292020-06-29
Method for the treatment of acute respiratory viral infection
RU2020122037A
(en)
The active ingredient of the drug, drug, pharmaceutical composition and method for the treatment of demyelinating diseases of a living organism, including disease prevention
The use of a drug having an antiviral effect for the prevention or treatment of SARS-CoV-2 coronavirus infection (variants) and a method for the prevention or treatment of SARS-CoV-2 (infection)